Monday, February 22, 2021 (HealthDay News)-Several new treatments related to aging Macular degeneration (AMD), Progressive eye The disease is under development. AMD is the main cause Vision loss In the elderly.
Approximately 11 million Americans suffer from AMD, which affects parts of the eye and allows you to see details. There are two types, wet and dry.Wet AMD is treated with one or two injections each month, and dry AMD Antioxidant vitamin, According to the American Academy of Ophthalmology.
“Current treatments have made a big difference in the lives of hundreds of thousands of people, but new treatments give hope to patients who were previously unable to treat AMD,” said retinal specialist Sneal. Dr. Garg, a clinical spokesman for the Academy, said.
“The new treatments also help patients receive more convenient and beneficial treatments than ever before,” he added in an Academy news release.
Treatment with antioxidant vitamins can help reduce vision loss in many patients with dry AMD, but there is no cure for patients with late-stage disease. However, many promising clinical trials are underway.
These include a study of two drugs that target parts of the immune system that have long been identified as a major factor in AMD.
Drugs that are injected directly into the eye have proven to be safe for people. According to the academy, the results of a significant improvement in vision are expected within about a year.
We are also investigating the replacement of vision cells that began to die late in dry AMD. Although treatment has shown early prospects, there is a long way to go before these stem cell therapies are ready for clinical use.
The main cause of wet AMD is Vascular Endothelial Growth Factor (VEGF), which causes the formation of weak blood vessels that leak into the retina.
Anti-VEGF injections appeared about 15 years ago to treat illness. Clinical trials have shown that such treatments are more than 90% effective against severe vision loss, but the actual rate is 50% because patients do not receive injections as often as they need to. The academy says it’s close. Most patients require injections every 4-8 weeks.
A promising new method is a small refillable drug reservoir that is surgically implanted in the eye just below the eyelids. The device is filled with a concentrated version of the anti-VEGF drug and delivered behind the eyes over a long period of time.
Instead of injecting every 6-8 weeks, patients may be replenished 1-2 times a year. Studies show that many people treated this way take 15 months between treatments.
The academy is also investigating gene therapy that allows the eye to make its own anti-VEGF drug.
For more information
National Eye Institute Age-related macular degeneration..
Source: American Academy of Ophthalmology, News Release, February 11, 2021
New hope for better macular degeneration treatment
Source link New hope for better macular degeneration treatment